Response of cluster headache to psilocybin and LSD
The authors interviewed 53 cluster headache patients who had used psilocybin or lysergic acid diethylamide (LSD) to treat their condition. Twenty-two of 26 psilocybin users reported that psilocybin aborted attacks; 25 of 48 psilocybin users and 7 of 8 LSD users reported cluster period termination; 18 of 19 psilocybin users and 4 of 5 LSD users reported remission period extension. Research on the effects of psilocybin and LSD on cluster headache may be warranted.
R Andrew Sewell, John H Halpern, Harrison G Pope Jr
More to read
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Clinical research with psychedelics has provided promising positive results for various mental disorders (Andersen et al., 2020; Bahji et al., 2020; Dos Santos et al., 2018; Vargas et al., 2020). However, sample sizes...
How Do Researchers Measure a Psychedelic Trip? The Power of 5D-ASC
The acronym 5D-ASC refers to Five-Dimensional Altered States of Consciousness. This framework offers researchers a powerful tool for analyzing and quantifying subjective experiences encountered during psychedelic journeys. Through careful development and empirical testing, 5D-ASC has emerged.
FDA Grants Accelerated Approval for as a Breakthrough Treatment for Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) granted accelerated approval for Leqembi (lecanemab-irmb) as a groundbreaking treatment. This marks a pivotal moment in the ongoing battle against Alzheimer's, with Leqembi being the second medication approved for the disease designed to tackle its fundamental pathophysiology.